NorthStrive Biosciences Expands AI Drug Discovery with Yuva, Targets Lead Nomination
ELAB is trading near its 52-week low of $5.06 (3.4% above the low) on light trading volume (0.1× avg).
Summary
NorthStrive Biosciences, a PMGC Holdings subsidiary, signed a First Amendment to its Development and License Agreement with Yuva Biosciences, launching a three-phase Expansion Program to advance four AI-discovered compounds toward lead nomination for cardiac disease and obesity. The program builds on positive Phase III results announced July 1, 2026, and is expected to take about six months. The amendment also strengthens the exclusive field of use and adds a right of first refusal across the broader cardiometabolic field. This is a meaningful step for a micro-cap company with a going concern warning, as it formalizes the next development stage and expands potential commercial rights. Watch for updates on Expansion Phase II confirmation results and the lead compound nomination expected from Phase III.
At the time of this announcement, ELAB was trading at $5.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2M. The 52-week trading range was $5.06 to $2,671.20. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.